Cerus Corporation

Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Sears Corporation's second quarter 2023 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Jessica Hanover, Cirrus's Vice President of Corporate Affairs.

Dr. Hanover, you may begin. Thank you and good afternoon.

I'd like to thank everyone for joining us today. As part of today's webcast, we are simultaneously displaying slides that you can follow. You can access the slides from the Investor Relations website at ir.cirrus.com. With me on the call are Obi Greenman, Cirrus's President and Chief Executive Officer, Vivek Jayaraman, Cirrus's Chief Operating Officer, Kevin Green, Cirrus's Chief Financial Officer, Dr. Nina Musti, Cirrus' Vice President of Development and Red Blood Cell Program Leader, Dr. Richard Benjamin, Cirrus' Chief Medical Officer, Dr. Lawrence Korash, Cirrus' Chief Scientific Officer, and Carol Moore, Cirrus' Senior Vice President of Regulatory Affairs and Quality. Cirrus issued a press release today announcing our financial results for the second quarter ended June 30, 2023, and describing the company's recent business highlights. You can access a copy of this announcement on the company website at www.siris.com. I'd like to remind you that some of the statements we will make on this call related to future events and performance rather than historical facts and our forward-looking statements. Examples of forward-looking statements include those related to our future financial and operating results, including our updated 2023 product revenue guidance, expected operating expense savings, our adjusted EBITDA goal, and future operating expenses, as well as our commercial development efforts, expected future growth and our growth strategy, future product sales, potential product launches, ongoing and future clinical trials, ongoing and future product development, and our regulatory plans and initiatives and related expectations, including the timing of these events and activities. These forward-looking statements involve risks and uncertainties that could cause actual events, performance, and results to differ materially. They are identified and described in today's press release and under risk factors in our Form 10-Q for the quarter ended June 30, 2023, which we will file shortly. We undertake no duty or obligation to update our forward-looking statements. On today's call, we will also be discussing non-GAAP financial measures, including non-GAAP adjusted EBITDA. These non-GAAP measures should be considered a supplement to and not a replacement for measures presented in accordance with GAAP. For reconciliation of non-GAAP financial measures to the most comparable GAAP financial measures, please refer to today's press release. We'll begin today with opening remarks from Obie, followed by Vivek to discuss recent business highlights, and Kevin to review our financial results and expectations for 2023. And now, it's my pleasure to introduce Obie Greenman, Cirrus's President and Chief Executive Officer.